| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –
–Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 in combination with pembrolizumab anticipated in fourth quarter of 2025 –
– Initiation of Phase 1/2 dose and regimen-finding clinical trial of WTX-330 expected in first quarter of 2025 –
– Cash guidance provides runway through at least the second quarter of 2026 –
WATERTOWN, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (NASDAQ:HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and outlined its strategic outlook and expected milestones for 2025.
Posted In: HOWL
